---
title: "Neurogene | 8-K: FY2026 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295529933.md"
datetime: "2026-08-11T11:35:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295529933.md)
  - [en](https://longbridge.com/en/news/295529933.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295529933.md)
generator: "portal-rs"
---

# Neurogene | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EBIT: As of FY2026 Q2, the actual value is USD -34.5 M.

#### Cash, Cash Equivalents and Short-Term Investments

Neurogene Inc. reported cash, cash equivalents, and short-term investments of $225.4 million as of June 30, 2026. Pro forma, including approximately $134.8 million in net proceeds from a July 2, 2026 public offering, these resources totaled approximately $360.2 million.

#### Research & Development (R&D) Expenses

R&D expenses were $25.5 million for the three months ended June 30, 2026, an increase from $19.4 million for the same period in 2025.

#### General & Administrative (G&A) Expenses

G&A expenses rose to $11.2 million for the three months ended June 30, 2026, from $6.7 million for the three months ended June 30, 2025.

#### Net Loss

Neurogene Inc. reported a net loss of -$34.5 million for the three months ended June 30, 2026, compared to a net loss of -$22.0 million for the three months ended June 30, 2025.

#### Operational Metrics - NGN-401 Program

Neurogene Inc. completed dosing for its Embolden registrational trial, involving 25 participants. Data from the Phase 1⁄2 trial of NGN-401 for Rett syndrome, as of June 16, 2026, indicated that 100% of participants improved in CGI-I score and gained at least one developmental milestone, with an average of 4.7 milestones per participant. No plateau or milestone loss was observed, and milestones were gained in a progressive, stepwise sequence. The NGN-401 1E15 vg dose was generally well-tolerated in the Phase 1⁄2 trial and Embolden (N=35) as of August 10, 2026, with no new treatment-related serious adverse events or dose-limiting toxicities observed in participants with at least 12 months of follow-up. The total safety database for NGN-401 includes 35 participants dosed at the 1E15 vg dose across both trials. The Phase 1⁄2 trial’s 80% response rate (8 of 10 participants) exceeded the pre-specified minimum response rate of 33% for success in the Embolden trial.

#### Unique Metrics (Rett Syndrome Specific Scales)

In the Phase 1⁄2 data, the Rett Syndrome Gross Motor Scale (RSGMS) showed a 5.2-point increase, significantly exceeding the 0.8-point decrease observed in natural history (p<0.001). For the Rett Syndrome Hand Function Scale (RSHFS), 100% of Phase 1⁄2 participants improved in hand function compared to 15% in natural history (p<0.001).

#### Manufacturing Capabilities

Neurogene Inc. has internal Chemistry, Manufacturing, and Controls (CMC) capabilities and operates a wholly owned, fully integrated in-house AAV manufacturing facility in Houston, spanning 42,000 sq ft, which includes 6,000 sq ft of cleanrooms.

#### Outlook / Guidance

Neurogene Inc. anticipates reporting topline data from the Embolden™ registrational trial in the second half of 2027. The company expects to complete Process Performance Qualification (PPQ) runs by the end of 2026 to support a Biologics License Application (BLA) submission. Its current cash resources are projected to fund planned operations into the first quarter of 2029, covering the Embolden data readout, BLA submission, and pre-commercial activities.

### Related Stocks

- [NGNE.US](https://longbridge.com/en/quote/NGNE.US.md)

## Related News & Research

- [Alexandria Real Estate Equities declares Q3 2026 dividend of R$ 0.63 per unit](https://longbridge.com/en/news/297928934.md)
- [Marisa updates financial events calendar for 2026](https://longbridge.com/en/news/297913424.md)
- [Quanta Services announces dividend of R$ 0.03 per unit for Q3 2026](https://longbridge.com/en/news/297931955.md)
- [LyondellBasell announces dividend of R$ 1.72 per unit for 3Q 2026](https://longbridge.com/en/news/297814383.md)
- [PulteGroup declares Q3 2026 dividend of R$ 0.9 per unit](https://longbridge.com/en/news/297931957.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**